Earn 1.25 AMA PRA Category 1 Credit(s)™, 1.25 contact hours for nursing professionals, 1.25 contact hours (.1 CEUs) for pharmacists, or 1.25 AAPA Category 1 CME credits
The rapidly expanding range of disease modifying therapies (DMTs) has changed the clinical approach to the management of patients with multiple sclerosis (MS). The emergence of numerous therapeutic options combined with the longevity and variable disease course of MS has led to the need to consider additional factors, such as safety, convenience, care during COVID-19, telehealth options, and the family planning process. Moreover, to ensure that patients receive optimal and timely therapy, early identification and diagnosis of those developing progressive disease is crucial. In this podcast series, experts in the field of MS review the current guidelines for the diagnosis and management of MS, and the roles of recent data of emerging therapies in the treatment algorithm.
This activity is supported by educational grants from Biogen; Sanofi Genzyme; and TG Therapeutics, Inc.